EVOLVE-MI: EVOLocumab Very Early After Myocardial Infarction

NCT05284747 · clinicaltrials.gov ↗

PHASE4

Phase

ACTIVE_NOT_RECRUITING

Status

6019

Enrollment

INDUSTRY

Sponsor class

Conditions

Cardiovascular Disease
Myocardial Infarction
Stroke
Coronary Revascularization

Interventions

DRUG: Evolocumab
DRUG: Routine Lipid Management

Sponsor

Amgen

Collaborators

[object Object]